effect achieved with intrathecal methotrexate alone." Our observations agree with this statement, confirming the inadequacy of cranial irradiation alone and emphasising the efficacy of the spinal component of craniospinal radiation.
inadequacy of cranial irradiation alone and emphasising the efficacy of the spinal component of craniospinal radiation.
The length of meningeal remission after craniospinal irradiation, reaching from one to over three years in five patients, establishes this schedule as a practical means of treating first episodes of overt meningeal leukaemia. The median duration of 99 weeks unmaintained meningeal remission was a conservative estimate. This would have been the figure if all three of the children dying without meningeal relapse had lived to develop it before this point. Although the numbers of patients were small this remission was longer than the longest previously reported median remission of 67 weeks,1 34 weeks,3 and over 33 weeks5 (obtained with maintenance intrathecal methotrexate given every eight weeks during remission). Our results were obtained without the added imposition of repeated intrathecal injections and their associated symptomatic side effects during remission. Craniospinal irradiation (2400 rads) without prior clearing of the CSF blast cells by methotrexate produced long-term remissions extending for eight to 43 months in 13 out of 32 children,6 but about a third of these patients showed meningeal relapse after a median duration of nine months (39 weeks), which suggests that slightly better results may be obtained when craniospinal irradiation is given after remission induced with intrathecal methotrexate, even though the spinal dose of irradiation is lower (1000 rads in the present study). The lower spinal dose was used in an effort to avoid undue marrow and immunosuppression in children who had already been on systemic antileukaemic chemotherapy for one or more years and who were likely to remain on such treatment for a similar period. The subsequent survival of five patients for one to more than three years after completion of the craniospinal radiotherapy indicates that this dose of spinal radiotherapy did not unduly compromise subsequent systemic chemotherapy.
Serious encephalopathyl 0-12 was not encountered in this trial.
There might, however, be a hazard of radiation-induced brain damage in patients given a second course of CNS irradiation who have already had cranial irradiation as a component of CNS prophylaxis early in their disease. This commonly applies to patients currently presenting with their first episode of meningeal leukaemia. Several such patients are now receiving a second course of cranial plus spinal irradiation, so far without a report of serious complication. This question, as well as that of the efficacy of the treatment in patients who have already had CNS prophylaxis, will therefore be answered in time.
Finally, the findings of the present trial may be relevant to the design of improved initial "prophylactic" treatment of the CNS, since this is similarly directed at eliminating small numbers of leukaemic cells in the CNS. For instance, the addition of 1000 rads to the spine might give a lower rate of meningeal relapse than intrathecal methotrexate and cranial irradiation alone. 12 Price, R A, and Jamieson, P A, Cancer, 1975, 35, 306. 13 868 The mode of action of sodium cromoglycate has been studied by many workers. We reported that protection against allergeninduced bronchoconstriction was significant at 30 minutes and five hours but not at 24 hours. Bronchial protection with sodium cromoglycate occurred during challenge with the same allergen given twice but not against a different allergen given five hours later,5 which suggests a mechanism of specific desensitisation of the bronchial mast cells. In a further study we assessed the effect of sodium cromoglycate on inhalation challenge with specific allergens as well as methacholine and histamine. 6 The degree of decrease in forced vital capacity (FVC) and forced expiratory volume in one second (FEV,) after allergen challenge was significantly reduced by sodium cromoglycace in 15 of the 17 patients (P <0 001). In the same patients sodium cromoglycate failed to show any significant difference from placebo in its effect on the bronchial response to histamine or methacholine. Kerr et al,7 however, reported that sodium cromoglycate completely protected against the fall in FVC and FEVy produced by an intravenous infusion of histamine.
The aim of the present study was to assess the protective effects of sodium cromoglycate in patients with asthma challenged with histamine given intravenously or by inhalation and with allergen given by inhalation.
Patients and methods
Nineteen patients were studied. Nine were male and 10 female, and their ages ranged from 14 to 54 (mean 29-5) years. All had longstanding bronchial asthma of moderate severity. All bronchodilators were stopped at least 12 hours and antihistamines 48 hours before the study. At the time of study no patient had any subjective symptoms of asthma. One was on prednisone 15 mg/day. Baseline pulse rate and blood pressure were determined and the chest was examined for wheezing. FVC and FEV, were measured and the results used as indices of lung function. Symptoms and physical findings were recorded throughout.
After the baseline determinations each patient received by spinhaler either two 20-mg capsules of sodium cromoglycate or two placebo capsules, treatment being allocated in a single-blind, randomised fashion. Thirty minutes later an intravenous infusion of histamine acidphosphate was begun at a rate of 12-3 ig of the salt (equivalent to 4 ig of the base) per minute for 10 minutes using a Harvard infusion pump. During the infusion spirometry was performed at five and 10 minutes, and blood pressure, heart rate, and any symptoms were recorded. Spirometry was again performed 5, 10, 15, 20, and 30 minutes after the infusion. Twenty-four hours later the experiment was repeated, the patients receiving the alternative compound.
Seventeen of the 19 patients were studied in a similar manner to determine the effects of sodium cromoglycate and placebo on the inhalation of histamine base 2 mg/ml by aerosol and an allergen extract. The specific allergen used was determined from the history and by skin tests. Altogether 7 patients were challenged with alternaria, 3 with ragweed, 1 with Russian thistle, I with burweed marsh elder, 2 with June grass, and 3 with house dust. The initial concentration used was 1000 protein nitrogen units (PNU)/ml. If less than a 20°h decrease in FEV, occurred a concentration of 10 000 PNU/ml was used. Sodium cromoglycate, two 20-mg capsules, and placebo were given by Spinhaler at random on alternate days 30 minutes before aerosol challenge with histamine acidphosphate, equivalent to No pronounced changes in pulse rate or blood pressure occurred after intravenous histamine. In 10 patients, however, the systolic blood pressure fell by 10 mm Hg, but in no case did this exceed 20 mm Hg.
Although all the patients showed a response to histamine inhalation with a fall in FEV, of greater than 20°, only 13 showed a response to intravenous infusion of histamine with a fall in FEV, of more than 10b/ (table I) . Baseline values of FEV, and FVC were 80% of the predicted values. Within five minutes after the intravenous infusion of histamine was stopped the FEV, had returned to the baseline value in the sodium cromoglycate group and almost to the baseline value in the placebo group. Fig 1 shows the percentage changes in FEV, induced by intravenous histamine in the patients who had a 1000 or more decrease in FEV,.
Five minutes after the start of the infusion of histamine both the placebo and sodium cromoglycate groups had a decrease in FEV, down to 84% of their baseline values. Within five minutes after stopping the infusion, however, the FEV, in the sodium cromoglycate group had returned to 99% of the baseline value, whereas the FEV, in the placebo group was only 92% of the baseline value. This difference was significant (P <0 05).
The changes in FVC induced by intravenous histamine in the two groups were similar (fig 2) , and, although the FVC 15 minutes after the infusion was greater in the sodium cromoglycate group, the differences were not statistically significant. Fig 3 shows the percentage falls in FEV1 after challenge with intravenous histamine, aerosol histamine, and aerosol allergen in these asthmatic patients. There was no significant difference in response to either intravenous or aerosol histamine between the sodium cromoglycate and placebo groups. Only 13 of the 19 patients responded to an intravenous infusion of histamine with a 10% or greater fall in FEVy, the mean decrease in these patients being only 16%. In contrast, all the patients who received histamine by aerosol responded, the mean decreases in FEV, being 37-8% after placebo and 35-5% after sodium cromoglycate. Again there was no protection with sodium cromoglycate. A significant degree of protection with sodium cromoglycate, however, occurred in 15 of the 17 patients after allergen challenge. After placebo and allergen challenge the mean decrease in FEV, was 37-5 i 3.4%, whereas after sodium cromoglycate the mean decrease was only 23-6 ± 3-6% (P<0-01).
Discussion
This study was undertaken to further elucidate the action of sodium cromoglycate on the bronchoconstriction produced by histamine. Kerr et al? reported that sodium cromoglycate completely inhibited the fall in vital capacity and FEV1 produced by intravenous infusion of histamine. They reported mean falls in FVC and FEV5 of 20% and 28%/ respectively in 10 asthmatic patients after 50 /sg histamine hydrochloride given intravenously. After 40 mg sodium cromoglycate they found no fall in vital capacity or FEV1 in response to histamine.
Ryo et a?6 the following year found no protection with sodium cromoglycate against aerosol inhalation of histamine or methacholine in 17 asthmatics who showed marked protection against allergen inhalation challenges. We therefore attempted to study the effect of sodium cromoglycate in the manner that Kerr et a?7 did on intravenously administered histamine in an effort to determine whether the action of sodium cromoglycate was different on intravenous versus aerosol histamine. The effect of histamine on smooth muscle may be produced by a direct action of the amine or by a delayed reflex action. 8 Simonsson et a?9 reported that the reflex action of-histamine is mediated by vagal pathways and is only partially blocked by atropine.
Regardless of the mechanism of histamine bronchoconstriction we were unable to show any protection by sodium cromoglycate against histamine by either route of administration. We are unable to explain the difference between our results and those of Kerr et al. 7 We found that the maximum effect of histamine occurred during the infusion period, the FEV1 returning almost to the baseline value within five minutes afterwards, whereas Kerr et al reported the maximum effect 20 minutes after the infusion. Possibly our patients had less severe asthma, since only 13 of the 19 showed more than a 10% fall in FEV1 with a mean of 16%, whereas the patients of Kerr et al showed a 28% fall in FEV1. Nevertheless, all our patients responded to aerosol histamine with a mean decrease in FEV, of 37%. Bronchial sensitivity to histamine appears to be much greater when the aerosol route is used. The intravenous route resulted in systemic symptoms in all patients, with severe headache in two. The increased sensitivity by the aerosol route and lack of any other systemic effects makes it the preferable route of administration in attempting to assess bronchial sensitivity.
The increase in FEV1 almost to the baseline value after histamine infusion and sodium cromoglycate and the increase to only 92% of the baseline value after histamine and placebo sodium cromoglycate. This effect was not due to a difference between the patients, since when we recalculated the results using the same 11 subjects for both placebo and sodium cromoglycate they were the same. Sodium cromoglycate has a slight phosphodiesterase inhibiting effect, which might explain the differences' 0; however, it has no effect on the histamine response of human bronchial smooth muscle.' We have also shown that sodium cromoglycate has no effect on tracheal smooth-muscle contraction induced by histamine or methacholine."1 It does, however, inhibit allergen contraction of the passively sensitised human tracheal smooth muscles. Our results of the lack of effect of sodium cromoglycate on histamine challenge are consistent with those of Pagelow.'2 He found no difference in the threshold of histamine bronchial reactivity with sodium cromoglycate or phentolamine. In contrast, Kerr et alt7 reported complete protection against histamine with both these agents. We have studied the effect of sodium cromoglycate in vitro on the alpha-receptor contraction of isolated human trachea induced by adrenaline in the presence of propranolol. In this system we are unable to show any inhibition by sodium cromoglycate of alpha-receptor contrac- Prematurity was judged by the clinical features of the newborn6 in conjunction with the obstetric estimate of gestation.
Results
The perinatal mortality rate in the 56 pregnancies reviewed was 110"/ and the incidence of premature delivery was 36%. Five fetal deaths occurred among 40 multigravid women, in contrast to a single fetal death among the 16 primigravid patients.
The ethnic composition of the group of mothers who developed intrahepatic cholestasis is shown in table 1. The proportion of patients with a Mediterranean ancestry was much greater than that of the overall population delivered at King George V Hospital. For cultural and religious reasons, few of these women had used oral contraceptives, but a history of jaundice in association with these drugs was obtained from three women. Five other patients had previously had a cholecystectomy and another woman had had viral hepatitis five years before her pregnancy. Ten patients had f-thalassaemia minor, one had sickle cell trait, and another suffered from congenital spherocytosis.
Incidence of jaundice and pruritis-Twenty-nine pregnancies were complicated by jaundice and pruritus and 27 by pruritus alone. The gestational period at which symptoms began varied from 13 to 37 weeks (mean 30 5 weeks). The mean interval between the onset of symptoms and delivery was six and a half weeks and was the same
